A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease

Stopped Terminated early at the Sponsor's discretion, not due to safety concerns.

Conditions

• Acute Graft-Versus-Host Disease
• GIGVHD

Interventions

• BIOLOGICAL: ALXN1007 10 mg/kg once weekly
• BIOLOGICAL: ALXN1007 20 mg/kg once weekly
• BIOLOGICAL: ALXN1007 20 mg/kg twice weekly

Sponsor

Alexion Pharmaceuticals, Inc.